Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area

Therapeutic Innovation & Regulatory Science
Shoyo ShibataTakeshi Suzuki

Abstract

A new incentive program, "Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc," was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as...Continue Reading

References

Jun 8, 1991·Journal of Health Economics·J A DiMasiL Lasagna
Nov 4, 1994·Journal of Health Economics·H G Grabowski, J M Vernon
Jun 8, 2004·The Journal of Economic Perspectives : a Journal of the American Economic Association·Ernst R Berndt
Dec 23, 2004·Frontiers in Health Policy Research·Patricia M Danzon, Jonathan D Ketcham
Mar 1, 2005·Irish Journal of Medical Science·P M Logan
May 25, 2005·International Journal of Health Care Finance and Economics·Anindya Sen
Jan 24, 2007·Health Economics·Marin C GemmillAlistair McGuire
Sep 23, 2008·American Journal of Therapeutics·Kenneth A GetzKenneth I Kaitin
Jul 23, 2013·Clinical Pharmacology and Therapeutics·K AsanoY Uyama
Jan 1, 2016·Therapeutic Innovation & Regulatory Science·Shoyo ShibataTakeshi Suzuki

❮ Previous
Next ❯

Citations

Jul 18, 2019·Therapeutic Innovation & Regulatory Science·Shoyo ShibataKoken Ozaki
Jan 1, 2017·Therapeutic Innovation & Regulatory Science·Takuma MatsudaAtsushi Aruga
May 2, 2018·Therapeutic Innovation & Regulatory Science·Shoyo ShibataTakeshi Suzuki
Sep 21, 2018·Therapeutic Innovation & Regulatory Science·Daigo FukumotoTakeshi Suzuki
Jan 1, 2017·Therapeutic Innovation & Regulatory Science·Shoyo ShibataTakeshi Suzuki
Nov 1, 2016·Therapeutic Innovation & Regulatory Science·Shoyo ShibataTakeshi Suzuki

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
David G Pfister
PLoS Medicine
Adriane Fugh-Berman, Douglas Melnick
© 2022 Meta ULC. All rights reserved